| Bioactivity | ICA (N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine) is a SK channel inhibitor that has antileishmanial activity with an IC50 of 2.1 µM. | ||||||||||||
| Target | IC50: 2.1 µM (Antileishmanial) | ||||||||||||
| Invitro | The SK channel inhibitor ICA exhibits antiarrhythmic effects. ICA prevents electrically induced runs of atrial fibrillation in the isolated right atrium and induces atrial postrepolarization refractoriness and depolarizes resting membrane potential. ICA at 1 to 10 μM slows conduction velocity. At increased pacing frequencies, SK channel inhibition by ICA (10-30 μM) demonstrates prominent depression of other sodium channel-dependent parameters[2]. | ||||||||||||
| Name | ICA | ||||||||||||
| CAS | 3374-88-7 | ||||||||||||
| Formula | C13H10N4S | ||||||||||||
| Molar Mass | 254.31 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Bhuniya D, et al. Aminothiazoles: Hit to lead development to identify antileishmanial agents. Eur J Med Chem. 2015 Sep 18;102:582-93. [2]. Skibsbye L, et al. Antiarrhythmic Mechanisms of SK Channel Inhibition in the Rat Atrium. J Cardiovasc Pharmacol. 2015 Aug;66(2):165-76. |